Full-Time
Posted on 7/2/2025
Provides customizable clinical research solutions
No salary listed
No H1B Sponsorship
United States
In Person
đź’°Finance & Banking (1) |
---|
Catalyst Clinical Research provides tailored clinical research solutions for the biopharmaceutical industry. Their services are divided into two main offerings: Catalyst Flex, which focuses on multi-therapeutic global resourcing and functional services, and Catalyst Oncology, a full-service clinical research organization specializing in oncology. With a team of over 500 professionals across the US, UK, and Europe, Catalyst emphasizes a customer-centric approach, developed over more than a decade of feedback from clients. This approach allows them to create flexible solutions that meet the specific needs of their customers. Catalyst stands out from competitors by prioritizing a people-first culture, promoting a healthy work-life balance for its employees, and ensuring they have the resources needed for success. The company's goal is to drive effective clinical development studies while fostering a supportive environment for both clients and staff.
Company Size
201-500
Company Stage
N/A
Total Funding
N/A
Headquarters
Wilmington, North Carolina
Founded
2013
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
CRO makes the list for the fifth consecutive yearWILMINGTON, N.C., Aug. 19, 2024 /PRNewswire/ -- Catalyst Clinical Research joined the 2024 Inc. 5000 list of the nation's fastest-growing private companies for its fifth consecutive year. This year Catalyst earned a spot at 2,740 with 185% growth during the past three years."We are honored to be recognized on the Inc. 5000, joining an incredible list of impressive companies. During a period of our global expansion, Catalyst continues to deliver high-quality clinical research services for our clients," says Nik Morton, President and CEO of Catalyst Clinical Research
Kristin Judge assumes leadership role for all commercial functionsWILMINGTON, N.C., Aug. 8, 2024 /PRNewswire/ -- Catalyst Clinical Research announced today that Kristin Judge is its first chief commercial officer (CCO). She assumed the role on July 29, 2024, and leads the company's commercial functions.Kristin Judge, Chief Commercial Officer, Catalyst Clinical Research"Kristin has the depth of commercial experience to support Catalyst's continued growth," said Nik Morton, President and CEO of Catalyst Clinical Research. "Her experience supporting biotech, and pharmaceutical customers with CRO services and life-sciences technologies will be invaluable. She has embraced Catalyst's culture and vision for a differentiated CRO, and will ensure our commercial team is best positioned to deliver strengthened sales performance and continued growth.""Catalyst aligns directly with my strong belief that you can have a company with a positive team culture, people who care about each other, leaders who embrace authenticity, and staff who help customers and thousands of patients and families around the world. What could be better than that?" Ms
Catalyst Clinical Research has named Kristin Judge as its first chief commercial officer (CCO).
Engagement coincides with National Cancer Survivors DayWILMINGTON, N.C., May 31, 2024 /PRNewswire/ -- Starting on June 2, National Cancer Survivors Day, Catalyst Oncology, the biotech-focused oncology CRO brand of Catalyst Clinical Research, will start a collaboration with Imerman Angels, a renowned nonprofit organization providing free, personalized one-on-one cancer support.Catalyst Oncology seeks to increase the visibility of the support and resources Imerman Angels makes available to cancer patients, survivors, and caregivers to ensure no one faces cancer alone."Catalyst is excited to collaborate with Imerman Angels, an organization that shares our dedication to improving the lives of those affected by cancer," said Keya Watkins, Senior Vice President, Catalyst Oncology. "This connection is a great reminder that we are part of a larger community that can make an impressive impact alongside Imerman Angels, which provides comprehensive support to patients and their families. This also reinforces Catalyst Oncology's commitment to help our innovative biotech clients develop therapies to support cancer patients.""We are looking forward to working with Catalyst Oncology," said Jonny Imerman, Co-founder and Chief Mission Officer, Imerman Angels. "Together, we can reach more individuals, provide more support, and make a greater impact in the cancer community."The collaboration will be marked at a private event on National Cancer Survivors Day, a day dedicated to honoring and celebrating cancer survivors, their families, and caregivers, which occurs during the American Society of Clinical Oncology (ASCO) annual conference in Chicago.About Catalyst OncologyCatalyst Oncology is a full-service, specialty clinical research organization (CRO) built to serve the global biotech industry. Backed by leading retention rates and a culture rooted in its core values, Catalyst Oncology provides customers with teams experienced across all functions, knowledgeable in complex drug classes and study designs, and with data-centric methodologies that help bring next-generation therapies to cancer patients.Catalyst Oncology is one of two established, branded solutions offered by Catalyst Clinical Research and employs more than 1,000 staff and several offices in the United States, Europe, and the Asia-Pacific region. Catalyst's flexible service model comes from more than a decade of listening to customers, devising customer-centric solutions, and helping customers advance clinical studies by leveraging expert teams and innovative technologies
Nik Morton brings decades of experience in clinical research with senior roles in global operations, digital clinical trials, biostatistics, site and patient accessWILMINGTON, N.C., Feb. 14, 2024 /PRNewswire/ -- Catalyst Clinical Research announces today that Nik Morton, the company's president and COO, assumed its CEO role on 12 February 2024. Mr. Morton joined Catalyst as its COO in 2022. Mr. Morton moved into his new position while Nick Dyer, Catalyst's former CEO, has shifted his focus to overseeing the strategic growth of the companies within Project Constellation Holdings, the parent company of Catalyst Clinical Research and Genpro Research.Nik Morton, CEO and President, Catalyst Clinical Research"Nik is an experienced clinical research executive and is uniquely qualified to assume this role," said Nick Dyer, Executive Chair for Project Constellation Holdings